Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET

Abstract Tumoral hypoxia correlates with worse outcomes in glioblastoma (GBM). While bevacizumab is routinely used to treat recurrent GBM, it may exacerbate hypoxia. Evofosfamide is a hypoxia-targeting prodrug being tested for recurrent GBM. To characterize resistance to bevacizumab and identify tho...

Full description

Bibliographic Details
Main Authors: Shiliang Huang, Joel E. Michalek, David A. Reardon, Patrick Y. Wen, John R. Floyd, Peter T. Fox, Geoffrey D. Clarke, Paul A. Jerabek, Kathleen M. Schmainda, Mark Muzi, Hyewon Hyun, Eudocia Quant Lee, Andrew J. Brenner
Format: Article
Language:English
Published: Nature Publishing Group 2021-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-84331-5

Internet

https://doi.org/10.1038/s41598-021-84331-5

Similar Items